University of Hull logo

Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?

Hodgkinson, Victoria C.; ELFadl, Dalia; Agarwal, Vijay; Garimella, Veerabhadram; Russell, Charlotte; Long, Ervine D.; Fox, John N.; McManus, Penelope L.; Mahapatra, Tapan K.; Kneeshaw, Peter J.; Drew, Philip J.; Lind, Michael J.; Cawkwell, Lynn

Authors

Victoria C. Hodgkinson

Dalia ELFadl

Vijay Agarwal

Veerabhadram Garimella

Charlotte Russell

Ervine D. Long

John N. Fox

Penelope L. McManus

Tapan K. Mahapatra

Peter J. Kneeshaw

Philip J. Drew

Professor Michael Lind M.J.Lind@hull.ac.uk
Foundation Professor of Oncology/ Head of the Joint Centre for Cancer Studies

Abstract

Introduction: Chemotherapy resistance is a major obstacle in effective neoadjuvant treatment for estrogen receptor-positive breast cancer. The ability to predict tumour response would allow chemotherapy administration to be directed towards only those patients who would benefit, thus maximising treatment efficiency. We aimed to identify putative protein biomarkers associated with chemotherapy resistance, using fresh tumour samples with antibody microarray analysis and then to perform pilot clinical validation experiments. Materials and methods: Chemotherapy resistant and chemotherapy sensitive tumour samples were collected from breast cancer patients who had received anthracycline based neoadjuvant therapy consisting of epirubicin with cyclophosphamide followed by docetaxel. A total of 5 comparative proteomics experiments were performed using invasive ductal carcinomas which demonstrated estrogen receptor positivity (luminal subtype). Protein expression was compared between chemotherapy resistant and chemotherapy sensitive tumour samples using the Panorama XPRESS Profiler725 antibody microarray containing 725 antibodies from a wide variety of cell signalling and apoptosis pathways. A pilot series of archival samples was used for clinical validation of putative predictive biomarkers. Results: AbMA analysis revealed 38 differentially expressed proteins which demonstrated at least 1.8 fold difference in expression in chemotherapy resistant tumours and 7 of these proteins (Zyxin, 14-3-3 theta/tau, tBID, Pinin, Bcl-xL, RIP and MyD88) were found in at least 2 experiments. Clinical validation in a pilot series of archival samples revealed 14-3-3 theta/tau and tBID to be significantly associated with chemotherapy resistance. Conclusions: For the first time, antibody microarrays have been used to identify proteins associated with chemotherapy resistance using fresh breast cancer tissue. We propose a potential role for 14-3-3 theta/tau and tBID as predictive biomarkers of neoadjuvant chemotherapy resistance in breast cancer. Further validation in a larger sample series is now required.

Journal Article Type Article
Publication Date Feb 2, 2012
Journal Journal of proteomics
Print ISSN 1874-3919
Electronic ISSN 1876-7737
Publisher Elsevier
Peer Reviewed Peer Reviewed
Volume 75
Issue 4
Pages 1276-1283
Institution Citation Hodgkinson, V. C., ELFadl, D., Agarwal, V., Garimella, V., Russell, C., Long, E. D., …Cawkwell, L. (2012). Proteomic identification of predictive biomarkers of resistance to neoadjuvant chemotherapy in luminal breast cancer: a possible role for 14-3-3 theta/tau and tBID?. Journal of Proteomics, 75(4), (1276-1283). doi:10.1016/j.jprot.2011.11.005. ISSN 1874-3919
DOI https://doi.org/10.1016/j.jprot.2011.11.005
Keywords Biophysics; Biochemistry
PMID 22115752